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BACKGROUND: Organ damage due to iron toxicity is one factor that increases the risk of getting cardiovascular and metabolic diseases in 
thalassemia patient. This study aims to determine glucose 
and lipid profiles in adolescents with thalassemia major and 
its association with iron overload in pancreas and liver.
METHODS: This was a cross sectional study. Subjects 
were thalassemia major adolescents without any 
confounding factors that may affect glucose and lipid levels. 
Blood samples were collected to measure the glucose level, 
lipid profiles, ferritin level and transferrin saturation. T2-
Magnetic Resonance Imaging was used to evaluate the iron 
overload in organs.  
RESULTS: From a total of 60 subjects, diabetes mellitus 
was diagnosed in 1 subject and impaired fasting glucose was 
diagnosed in 3 subjects. All subjects had high triglycerides/
high density lipoprotein-cholesterol (HDL-C) ratio, 59 
subjects (98%) had low HDL-C, 18 subjects (30%) had 
hypertriglyceridemia, and none had abnormal high level of 
low density lipoprotein-cholesterol (LDL-C). The majority 
of subjects had ferritin ≥2,500 ng/mL (70%), mild pancreatic 
iron overload (56.6%), and moderate hepatic iron overload 
(43.8%). Degree of hyperferritinemia was not associated 
with glucose and lipid profiles. Blood glucose profiles 
were not associated with various degree of pancreatic iron 
overload. Similar result was also observed between lipid 
profiles and hepatic iron overload. 
CONCLUSION: Abnormal glucose and lipid profiles in 
thalassemia major can be found in adolescence. Normal 
blood glucose level isn’t necessarily associated with normal 
pancreatic iron deposition. Hepatic iron overload may 
worsen dyslipidemia in thalassemia major patients.  
KEywORDS: glucose profile, lipid profile, pancreatic iron 
overload, hepatic iron overload, thalassemia major
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Abstract
Introduction
Thalassemia is an autosomal recessive disorder, 
characterized by decrease or absence in production of 
globin chain.(1) As the most common single gene disorder, 
around 300 mutations in β-globin gene and 100 mutations in 
α-globin gene have been found around the world.(2) Patient 
with homozygous or severe mutation usually presents 
as thalassemia major, indicated by the need of life-long 
transfusion to correct severe anemia.(3) 
 The most common complication related to regular 
transfusion is iron overload.(3) Liver and pancreas are 
two organs with high iron storage capacity.(4) These two 
organs play an essential role in metabolism. The liver 
regulates cholesterol metabolism and the pancreas controls 
blood glucose levels by producing insulin hormone and its 
counter-regulatory hormone glucagon.(5-7)
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 In the last decades, thalassemia major patients tend 
to have better survival rate as a result of novel therapeutic 
and complications prevention strategies. Those strategies 
include the improvement of blood quality, invention of 
new oral iron chelator, better adherence with iron chelation 
treatment, therapy starting at earlier age, and availability of 
T2-Magnetic Resonance Imaging (MRI) to assess degree 
of iron  deposition  in  organs.(8,9)  With  this  prolonged 
survival, chronic complications in thalassemia major 
patients, such as metabolic syndrome and cardiac disease, 
cannot be avoided. 
 Many pathogeneses of chronic disease, such as 
atherogenesis and insulin resistance, have started since 
the adolescence or earlier period in life.(10-12) Therefore, 
detecting metabolic abnormalities at a young age is very 
important. We are interested in looking upon glucose and 
lipid  profiles  in  adolescent  thalassemia  major  patient 
because there are still limited studies available in this field. 
We also aimed to determine the association between glucose 
profiles with pancreatic iron overload, as well as lipid 
profiles with hepatic iron overload.
Methods
This was a cross sectional study conducted at Cipto 
Mangunkusumo Hospital, Jakarta, Indonesia. This study 
had been approved by ethical committee of Faculty of 
Medicine, Universitas Indonesia - Cipto Mangunkusumo 
Hospital, Jakarta (No. 1113/UN2.F1/ETIK/2018).
 We estimated the sample size using sample estimation 
formula  for  measuring  mean  difference  between  two 
groups, with α=0.05 and β=0.8. Pooled estimate of the 
variance was obtained from previous researches.(13-14) 
Mean glucose and cholesterol levels were assumed as 
clinically significant if the differences were 10 mg/dL and 
20 mg/dL, respectively. A minimum of 60 adolescents (age 
12-18 year) with thalassemia major must be recruited for 
this study. Subjects were excluded from the study if they 
were on diet program or consumed certain drugs, including 
antidiabetic, antiobesity, and steroid drugs. 
 Pre-transfusion fasting blood samples were collected 
to measure fasting blood glucose, lipid profiles (triglyceride, 
total cholesterol, high density lipoprotein-cholesterol 
(HDL-C), and high density lipoprotein-cholesterol 
(LDL-C), ferritin and transferrin saturation. After that, 
subject was given 75 g glucose to measure 2-hour post-load 
blood glucose (2hPG) level. 
 Hyperferritinemia was categorized into two groups: 
1,000-2,500 ng/mL and  ≥2,500 ng/mL.(15) Diabetes 
mellitus was defined by fasting plasma glucose (FPG) 
level  ≥126 mg/dL  or  2hPG  level  ≥200  mg/dL.  Isolated 
impaired fasting glycaemia (IFG) was defined by FPG 
level 100-125 mg/dL and 2hPG level <140 mg/dL. Isolated 
impaired glucose tolerance (IGT) was defined by FPG 
level <100 mg/dL and 2hPG level 140-199 mg/dL.(16-18) 
Hypertriglyceridemia was defined by a cut-off ≥150 mg/
dL.(16) High LDL-C and triglyceride/HDL-C were defined 
by a level ≥130 mg/dL and ≥2.2, respectively.(19,20) Low 
HDL-C was defined by a value <40 mg/dL.(21)
 Degree of iron deposition in pancreas and liver was 
assessed using T2-MRI 1.5 Tesla (CMRtools, Siemens 
Avanto, Erlangen, Germany). Degree of pancreatic iron 
deposition was classified as follow: normal >33 ms, mild 
10-33 ms, moderate 2.5-10 ms, severe <2.5 ms. Degree of 
hepatic iron deposition was classified as follow: normal 
>6.3 ms, mild 2.7-6.3 ms, moderate 1.4-2.7 ms, severe <1.4 
ms.(22,23) 
 Data results were presented as numeric data and 
analyzed using SPSS 20.0 (IBM, Chicago, USA). The 
relationship between degree of hyperferritinemia with 
glucose and lipid level were analyzed using unpaired t-test 
analysis. Meanwhile, data analysis between iron overload in 
organs (based on T2-MRI) with glucose and lipid level were 
performed with Kruskal-Wallis.
A total of 60 subjects were recruited in this study. The 
number of male and female subjects were almost equal. 
Most of the subjects were diagnosed with β-thalassemia 
(51.7%) and β-thalassemia/HbE (45%). Deferiprone (DFP) 
was  the  most  common  iron  chelator,  either  as  single 
therapy  or  combined  with  deferasirox  (DFX) . None 
of them used deferoxamine (DFO) as single iron chelator 
(Table 1).
 One subject was diagnosed with diabetes mellitus and 
3 subjects were diagnosed with IFG. Subject with diabetes 
mellitus was 16 years old boy. He had been diagnosed 
with beta-thalassemia major when he was 19-months old. 
He used single DFP iron chelator with dosage of 75 mg/
kg body weight/day. There were 18 subjects diagnosed with 
hypertriglyceridemia, but none with high LDL-C. Most 
subjects had low HDL-C and high triglyceride/HDL-C 
ratio. Based on serum ferritin level, most of the subjects 
(70%) had ferritin level ≥2500 ng/mL. T2-MRI examination 
showed that subjects predominantly had mild pancreatic 
iron overload (56.6%) and moderate  hepatic iron overload 
(43.8%) (Table 2).
Results
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Variables n = 60
Age, mean (SD) years 15 (1.89)
Gender, n (%)
Male 32 (53.3)
Female 28 (46.7)
Type of thalassemia, n (%)
α-thalassemia 2 (3.3)
β-thalassemia 31 (51.7)
β-thalassemia/HbE 27 (45)
Type of chelation, n (%)
DFP 31 (51.7)
DFX 6 (10)
DFO+DFP 8 (13.3)
DFO+DFX 1 (1.7)
DFP+DFX 14 (23.3)
Table 1. Demographic characteristics of subjects.
Variables n = 60
Glucose tolerance test, mean (SD) mg/dL
FPG 90.14 (22.72)
2hPG 98.78 (19.72)
Glucose abnormalities, n (%)
Diabetes mellitus 1 (1.7)
Isolated IFG 3 (5)
Lipid profile, mean (SD) mg/dL
Triglyceride 143.16 (50.02)
Total-C 94.24 (22.41)
HDL-C 20.70 (7.53)
LDL-C 54.22 (17.49)
Triglyceride/HDL-C ratio 7.85 (4.63)
Lipid abnormalities, n (%)
Hypertriglyceridemia 18 (30)
High triglyceride/HDL-C 60 (100)
Low HDL-C 59 (98)
Ferritin, median (min-max) ng/mL 3565 (1013 - 14126)
Transferrin saturation, median (min-max) % 89.5 (30 - 100)
Degree of hyperferritinemia, n (%)
1,000-2,500 ng/mL 18 (30)
≥2,500 ng/mL 42 (70)
Pancreatic iron overload, n (%)
Normal 13 (21.7)
Mild 34 (56.6)
Moderate 13 (21.7)
Hepatic iron overload, n (%)
Normal  3 (4.2)
Mild  15 (25)
Moderate  26 (43.8)
Severe  16 (27)
Table 2. Glucose profile, lipid profile and iron overload in 
organs.
 In general, the degree of hyperferritinemia did 
not significantly affect glucose and lipid profiles (Table 
3). Glucose profiles were not related with the degree of 
pancreatic iron overload (Table 4). 
 The  degree of  hepatic  iron  overload  was  not 
associated with lipid profiles. Following the increased 
severity of hepatic iron overload, the trend of triglyceride 
level and triglyceride/HDL-C ratio were positive, but the 
trend of total cholesterol, HDL-C, and LDL-C levels were 
negative (Table 5).
Discussion
Iron  overload  is  one  of  the  main  complications  in 
thalassemia major patients. It induces cell death and organ 
damages by generating reactive oxygen species (ROS). 
Evaluating  iron  overload  in  organs  is  crucial  for 
thalassemia major patients. In our study, we found that most 
adolescents  with  thalassemia  major  had  mild  pancreatic 
iron overload and moderate hepatic iron overload. Another 
study observed that iron deposition in thalassemia major 
children has occurred before adolescence.(4) 
 Serum ferritin level was not associated with glucose 
and lipid levels. It may be explained by the fact that serum 
ferritin is sensitive, but not specific to express iron level in 
the body.(24) Many factors may affect serum ferritin level, 
including dietary intake of iron-rich products, obesity, 
inflammation, liver disease, and alcohol consumption.(25) 
Therefore, T2-MRI examination is essential to directly 
measure iron deposition in organs.(4)
 In this study, we diagnosed 1 subject with diabetes 
mellitus, 3 subjects with IFG, and none with IGT. These 
findings  indicate  that  the  abnormality  of  glucose 
metabolism  in  thalassemia  major  has  started  early in 
life. On the contrary, MRI examination showed that most 
subjects had abnormal pancreatic iron deposition. This 
DFP: deferiprone; DFX: deferasirox; DFO: deferoxamine.
FPG: fasting plasma glucose; 2hPG: 2-hour post-load blood 
glucose; IFG: impaired fasting glycaemia; Total-C: total 
cholesterol; HDL-C: high density lipoprotein-cholesterol; LDL-C: 
low density lipoprotein-cholesterol.
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Hyperferritinemia FPG 2hPG Triglyceride Total-C HDL-C LDL-C Triglyceride/HDL-C Ratio
1,000-2,500 ng/mL 89.00 ± 9.97 96.53 ± 15.05 132.27 ± 25.47 90.33 ± 15.25 20.47 ± 5.62 52.13 ± 10.62 6.99 ±  2.25
≥2,500 ng/mL 90.61 ± 9.24 99.72 ± 21.49 150.39 ± 58.13 97.83 ± 24.27 21.22 ± 8.4 56.42 ± 19.68 8.25 ± 5.36
p -value* 0.596 0.550 0.088 0.08 0.509 0.165 0.766
Table 3. Blood glucose and lipid profile level in different degree of iron overload. 
discrepancy was also observed by other studies.(26,27) 
These results may imply two possibilities; firstly, despite 
damaged of pancreas caused by iron excess, production of 
pancreatic hormones is still normal. Another possibility is 
the compensatory mechanism  in human body maintaining 
glucose  homeostasis  even  when  the  production  of 
pancreatic hormones has decreased. Further studies 
including the direct measurement of insulin level are 
important to explain these findings. 
 Long term glycemic monitoring is also important in 
thalassemia major. Two indicators that have been used in 
some studies are HbA1C and fructosamine. Fructosamine, 
a product resulted from glycation reaction between glucose 
and protein, is believed to be useful in patients with 
hemolytic anemia or hemoglobinopathies. However, studies 
comparing these markers show inconsistent results.(28,29)
Liver iron overload in thalassemia major patients causes 
impairment on its function.(30,31) Theoretically, liver plays 
an important role in production, storage, and metabolism 
of lipid and lipoprotein in the body. One study finds that 
HDL-C and LDL-C levels are significantly affected by the 
severity of liver injury in non-alcoholic liver cirrhosis.(32) 
 In  this  study,  we  found  that  dyslipidemia  in 
thalassemia major patients, especially high triglyceride/
HDL-C ratio and low HDL-C level, had started at early 
age. Hypocholesterolemia in thalassemia patients may 
be caused by cytokines release from macrophage system 
Mean ± SD 
(mg/dL) p -value* 
Mean ± SD 
(mg/dL) p -value*
Normal 91.50 ± 3.59 98.80 ± 24.54
Mild 87.19 ± 8.94 96.12 ± 17.44
Moderate 94.20 ± 8.54 105.40 ± 23.36
Pancreatic 
Iron Overload
FPG 2hPG
0.071 0.703
Table 4. Blood glucose level in various degree of pancreatic iron deposition.
that impact hepatic secretion. Another factor is increased 
cholesterol uptake by macrophage to be used as membrane 
cell component during accelerated erythropoiesis in 
reticuloendothelial system.(33-35)
 Despite having low LDL-C level, all subjects had 
high triglyceride/HDL-C ratio. This ratio is a good predictor 
for cardiometabolic risk (CMR) and insulin resistance 
in children.(36,37) It is inversely related to large LDL-C 
concentration and positively related to small LDL-C 
concentration.(38) Although all subjects in our study had 
normal level of LDL-C, but its proportion was dominated 
by small dense LDL-C. Previous study had proven that the 
small dense LDL-C has the highest atherogenic potential 
among lipoproteins in body.(39) In addition, nearly all 
subjects had low HDL-C level, which indicates impairment 
of scavenger mechanism to remove cholesterol and 
phospholipid  molecules  from  cells  and  hence  increases 
risk of atherosclerosis.(40)
 We observed specific pattern of lipid profiles following 
increase in severity of hepatic iron overload, although the 
association between them was not significant. Triglyceride 
level and triglyceride/HDL-C ratio increased following 
the severity of hepatic iron overload. Meanwhile, HDL 
and LDL cholesterol level decreased, with the lowest level 
found in subjects with severe hepatic iron overload. Hepatic 
iron toxicity causes a decrease of apolipoprotein A and B 
production.(35) Therefore, hepatic iron toxicity should be 
*p-value tested with unpaired t-test. FPG: fasting plasma glucose; 2hPG: 2-hour post-load blood glucose; Total-C: total cholesterol; 
HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein-cholesterol.
*p-value tested with Kruskal Wallis, comparison between normal, mild and moderate 
group. FPG: fasting plasma glucose; 2hPG: 2-hour post-load blood glucose;
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Mean ± SD
(mg/dL) p -value* 
Mean ± SD
(mg/dL) p -value* 
Mean ± SD
(mg/dL) p -value* 
Mean ± SD
(mg/dL) p -value* 
Mean ± SD
(mg/dL) p -value* 
Normal 140.50 ± 28.99 98.50 ± 31.82 28.00 ± 11.31 55.00 ± 16.97 5.23 ± 1.08
Mild 134.92 ± 21.72 102.58 ± 30.70 23.33 ± 8.61 60.42 ± 23.02 6.43 ± 2.17
Moderate 144.09 ± 42.37 95.38 ± 19.89 21.19 ± 8.50 54.10 ± 16.82 7.79 ± 3.64
Severe 157.77 ± 82.31 83.54 ± 14.23 16.69 ± 3.23 46.54 ± 11.54 10.33 ± 4.48
Triglyceride/HDL-CHepatic 
Iron 
Overload
Triglyceride Total-C HDL-C LDL-C
0.991 0.384 0.065 0.357 0.327
Table 5. Lipid profiles level in various degree of hepatic iron deposition.
Conclusion
Abnormalities  of  glucose  and  lipid  metabolism  in 
thalassemia  major  patients  has  developed  since 
adolescence. Pancreatic iron overload may have existed 
before abnormalities of glucose metabolism is detected. 
Hepatic iron overload may worsen dyslipidemia in 
thalassemia major patients.  
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